INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Inovio Pharmaceuticals priced an underwritten public offering on November 5, 2026 of 58,747,235 common shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049/warrant, with an overallotment option for 10,714,285 additional shares. Gross proceeds ~$75M before underwriting discounts (~3.1% discount to shares). Lead underwriters: Jefferies LLC and Piper Sandler Co.; H.C. Wainwright Co. as lead manager. Expected close ~November 9, 2026. Warrant exercise price $0.001/share with standard anti-dilution adjustments.
Why this rating
Equity raise of ~$75M is ~101% of company's $74.3M market cap—materially dilutive and transformative to capital structure, though execution is core/standard equity finance for small-cap biotech. Positive for runway; negative for shareholder dilution.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-6.9% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.37 ▲ 8.04% | at our read · unknown $1.27 | +10 min · unknown $1.29 ▲ 1.42% | +30 min · unknown $1.36 ▲ 7.65% | +1 hr · unknown $1.40 ▲ 10.02% | +4 hrs · unknown $1.56 ▲ 23.42% |
The stock had already moved -7.45% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.